Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB-008
- Development stage
- Preclinical
- Lead developer
- Polpharma Biologics
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
PB-008 is a biosimilar drug candidate developed by Polpharma Biologics. It is classified as an antineoplastic (anti-cancer) agent and is being investigated for the treatment of cancers (neoplasms). The specific reference product for this biosimilar has not been publicly disclosed, and its precise mechanism of action remains undefined in available sources. As of the latest updates, there are no reported clinical development phases beyond preclinical or pending status, and no recent progress has been noted in clinical trials or approvals[1][3].
Beyond the preview
Go deeper on PB-008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB-008.